Trevarx Biomedical, Inc. Company Profile, Contacts & Intelligence

Biotechnology Research3675 Market St3 employeesFounded 2016
Employees
3
Company source estimate

Trevarx Biomedical, Inc. Overview

Trevarx develops small molecule radiopharmaceutical platforms focusing on oncology. Its first platform is a PARP inhibitor (PARPi) analogue with an α-emitting radioligand therapy [211At]PTT (currently in pre-clinical stage) with published proof of concept in neuroblastoma seeking additional indications in adult PARP-1 tumors. Trevarx's PARPi platform has a companion PET biomarker [18F]FTT (entering Phase 2 Multi-Center trials in breast cancer in Spring 2022, led by MD Anderson Cancer Center).

Headquarters
3675 Market St
Industry
Biotechnology Research
Founded
2016
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

Trevarx Biomedical, Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Trevarx Biomedical, Inc. People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Trevarx Biomedical, Inc.

Explore companies in related markets and compare their industry and employee estimates.

Company Industry / match Employee estimate Page
Aro Biotherapeutics Biotechnology 52 View company
NUCLIDIUM AG Biotechnology Research 20 View company
Bound Therapeutics Biotechnology Research 6 View company
Higher Medicine Biotechnology Research 5 View company
BioLattice Biotechnology Research 3 View company
Cerespectus™ Medical Equipment Manufacturing 3 View company
DRS.LINQ Medical Equipment Manufacturing 3 View company
QuneUp® Software Development 1 View company
Ajaya Bio Biotechnology Research Not listed View company
Valfard Therapeutics Biotechnology Research Not listed View company